



Trendlines Medical Singapore Incorporates its Sixth Start-Up Company; Delivering Partnership Outcomes with National Healthcare Group and A*cceleerate

Misgav, Israel and Singapore 24 Jan 2019 – The Trendlines Group Ltd. (the “**Company**”) together with its subsidiaries, “**Trendlines**” or the “**Group**”) (SGX: 42T; OTCQX: TRNLY), a leading Israeli-based investment and innovation commercialisation company focused on early-stage, high growth medical and agricultural technologies, announced today that its wholly owned subsidiary, Trendlines Medical Singapore Pte. Ltd. (“**Trendlines Medical Singapore**”), established four additional medical technology start-up companies in 2018, a total of six start-ups since its inception in February 2017.

One of the recently incorporated companies, Medulla Pro Technology Pte. Ltd. (“**Medulla Pro**”) resulted from the partnership with the National Healthcare Group (“**NHG**”). Medulla Pro is focused on developing a real-time ultrasound-guided imaging system for lumbar puncture, an idea conceptualised by two clinicians from NHG.

Trendlines Medical Singapore Chairman Todd Dollinger said, “Partnership is at the core of our culture at Trendlines. Our collaboration with NHG aims to identify and develop promising early-stage ideas to address unmet medical needs. Medulla Pro’s management team will have the opportunity to leverage on the clinical experience of NHG. Additionally, the team will have the opportunity of working alongside experienced researchers at A*Star, the parent company of A*cceleerate, with whom we established a partnership in November 2018. We are confident that the active partnership with NHG and A*cceleerate, combined with our experienced product development engineers at Trendlines Labs, will provide Medulla Pro with the opportunity to deliver clinical solutions expediently.”

Director of NHG’s Centre for Medical Technologies & Innovation (CMTi), and Tan Tock Seng Hospital (TTSH)’s Chairman Medical Board Associate Professor Thomas Lew added, “The intent of NHG’s partnership with Trendlines Medical Singapore is to combine its technological capabilities with our clinical expertise to co-develop innovative solutions to enhance healthcare delivery to our population. This collaboration has shown promising results with examples such as the development of a smart auto body-pressure redistributor mattress-overlay to reduce the incidence of pressure ulcers in bed-

bound patients, and the early development of a real-time imaging solution for common procedures such as the lumbar puncture. We will continue to work with Trendlines Medical Singapore to identify more potential partnerships in our shared purpose of providing quality, safe and value-based patient care.”

Another Trendlines Medical Singapore’s start-up, AyzerSense Technology Pte Ltd (“**Ayzer Sense**”), established in May 2018, is working with NHG to evaluate a unique solution that reduces the occurrence of pressure ulcers in patients. Pressure ulcers are a worldwide concern and the debilitating effects result in a healthcare burden in excess of US\$10 billion in the United States¹ alone. Ayzer Sense will be completing a prototype of its overlay that automatically senses body pressure and redistributes excessive pressure points to reduce the occurrence of pressure ulcers. The technology from Ngee Ann Polytechnic (“**Ngee Ann**”) is now assigned to Ayzer Sense and has been further developed by the Company’s Chief Technology Officer Johnny Chee, a former lecturer at Ngee Ann.

Enterprise Singapore Director of Healthcare and Biomedical Johnny Teo said, “Enterprise Singapore is pleased to note the major milestone made by Trendlines Medical Singapore to groom more innovative medtech startups. Given the complexity of the sector, it is increasingly important to adopt a multi-disciplinary approach that combines clinical, research and commercialisation expertise in bringing a medtech product to market. This tripartite partnership between Trendlines Medical Singapore, NHG and A*ccelerate is a good example. By tapping into each other’s medical expertise, infrastructure and IP, they can develop commercial solutions that address unmet clinical needs in a shorter time.”

“At Trendlines Medical Singapore, we value our partners – entrepreneurs, clinicians, researchers, business mentors, and other stakeholders. We believe the combined impact of these experts will create greater dynamics to realise the full potential of a technologically focused company. It is with this belief that we have a team of dedicated, experienced individuals at Trendlines Medical Singapore who work closely with our six portfolio companies to realize their full commercial potential and look forward to evaluating additional new, exciting technologies to incubate more companies this year,” added Trendlines Medical Singapore CEO Eric Loh.

Trendlines Medical Singapore is an appointed Startup SG Accelerator by Enterprise Singapore catalysing the growth opportunities for high potential startups.

¹ Source: <https://www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/putool1.html>

About Trendlines Medical Singapore Pte Ltd

Trendlines Medical Singapore is a medical technology start-up incubator established by Trendlines and B. Braun, one of the world's leading medical device companies. Trendlines Medical Singapore discovers, invests in, incubates, and provides broad-ranging support to nurture and develop Singapore-based novel medical device companies with a view toward success in the global market.

About The Trendlines Group Ltd

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. An intensely hands-on investor, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

About National Healthcare Group

The National Healthcare Group (NHG) is a leader in public healthcare in Singapore, recognised at home and abroad for the quality of its medical expertise and facilities. Care is provided through an integrated network of six primary care polyclinics, acute care and tertiary hospitals, national specialty centres and business divisions. Together they bring a rich legacy of medical expertise to our philosophy of integrated patient-centred care.

NHG's vision is "Adding Years of Healthy Life". This vision goes beyond merely healing the sick to the more difficult and infinitely more rewarding task of preventing illness and preserving health and quality of life. With some 18,000 staff, NHG aims to provide care that is patient-centric, accessible, seamless, comprehensive, appropriate and cost-effective. As the Regional Health System (RHS) for Central Singapore, it is vital for NHG to partner and collaborate with stakeholders, community advisors, and voluntary welfare organisations. Together with our patients, their families and caregivers, we aim to deliver integrated healthcare services and programmes that help in Adding Years of Healthy Life to all concerned. More information is available at www.nhg.com.sg.

About Centre for Medical Technologies & Innovations (CMTi)

The National Healthcare Group's CMTi was established to support and drive medical technology innovations within the 18,000-strong NHG workforce and institutions. It seeks to bridge the gap between clinical problem statements or innovative improvement ideas and technology development, by identifying and facilitating collaboration between NHG institutions and partners, to co-develop implementable and scalable solutions to unmet clinical needs. CMTi is guided by the objective of delivering quality, safe, and value-based patient care. To date, CMTi has successfully worked with several local partners in the co-development of innovative products and solutions which have been used within NHG, in Singapore, and overseas.

About Enterprise Singapore

Enterprise Singapore, formerly International Enterprise Singapore and SPRING Singapore, is the government agency championing enterprise development. We work with committed companies to build capabilities, innovate and internationalise.

We also support the growth of Singapore as a hub for global trading and startups. As the national standards and accreditation body, we continue to build trust in Singapore's product and services through quality and standards.

Visit www.enterprisesg.gov.sg for more information.

Investor Contact Information

Israel

Shira Zimmerman, The Trendlines Group

shira@trendlines.com

Tel: +972.72.260.7000

Singapore

Reyna MEI, Financial PR

reyna@financialpr.com.sg

Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

GENERAL ANNOUNCEMENT::PRESS RELEASE - TRENDLINES MEDICAL SINGAPORE DELIVERS PARTNERSHIP OUTCOMES

Issuer & Securities

Issuer/ Manager

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

24-Jan-2019 12:04:10

Status

New

Announcement Sub Title

Press Release - Trendlines Medical Singapore Delivers Partnership Outcomes

Announcement Reference

SG190124OTHRGX9N

Submitted By (Co./ Ind. Name)

Haim Brosh